Julie Grant

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company’s platform of unique molecular entities selectively affects inflamed nociceptors. Treatment using this approach aims to provide more durable and robust local analgesic effects while minimizing numbness or paralysis and other systemic off-target effects. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons including chronic cough, pain and itch.

The Biden Cancer Initiative is determined to bring urgency to the fight against cancer and to transform cancer research and care systems for the 21st century. The Initiative brings to life Vice President Joe Biden and Dr. Jill Biden’s vision of a day when we can effectively prevent, diagnose, treat and care for every cancer patient. We are an independent nonprofit organization that builds on the Cancer Moonshot’s goals and impact and that channels what we learned from that effort into programs that will make a real difference in the lives of patients for generations to come.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Our platform enables us to discover peptides in a de novo fashion with the desired degree of potency, specificity and selectivity, and also engineer oral stability with specific peptidomimetic and chemical modifications.

Glooko enhances health outcomes of people with diabetes through personalized, intelligent, connected care platforms. Our proven technologies make lives better by revolutionizing the connection between patients and providers, as well as driving patient engagement and adherence via digital insights. Glooko solutions are globally deployed in more than 30 countries, 10,000+ clinical locations and integrated with over 200 devices.

Chrono Therapeutics is focused on improving clinical outcomes for patients battling addictions and living with neurological disorders via our proprietary Digital Patch platform, pioneering a new era of transdermal drug delivery designed to meet each patient's individual needs. By integrating timed drug delivery with personalized, mobile-phone-based digital support and unique data analytics to maximize compliance, we help patients manage hard to treat conditions and optimize clinical outcomes. We have multiple programs in active development that address significant market opportunities with unmet (or poorly) met needs. Each of our programs leverages medications that readily cross the skin. In addition to the programs currently in development for smoking cessation, Parkinson's Disease dyskinesia and prescription opioid dependence, our discovery pipeline is robust, with a number of CNS indications under evaluation that would benefit from a therapeutic combined with behavioral and compliance support.

Cellular Research, Inc., is a pioneering biotechnology research and development company founded in 2011 by innovators from Silicon Valley and Stanford University. Our mission is to revolutionize life science research by enabling high resolution investigation of single cells and limited samples. Our first two product lines Pixel and Precise deliver the power of Molecular Indexing to customers interested in high accuracy and precision for Gene Expression Studies.

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected. We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population. CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category. CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.

LABRYS BIOLOGICS, INC. is a biotechnology company based out of 1810 GATEWAY DRIVE, SAN MATEO, California, United States.

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. We are committed to understanding and addressing the needs of both patients and physicians, and using our experience and insight to identify and develop leading-edge medical dermatology clinical programs. Our goal is to help transform the way skin conditions are treated by serving as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology. Learn more about who we are and what we do by visiting Dermira.com. Here are our community guidelines: https://bit.ly/2rH5IuL

Biotech start-up in formation and founding phase. Attempting to raise money for Round A.

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With a diversified fund and over 200 exits to date, Canaan has invested in some of the worlds leading technology and healthcare companies over the past 33+ years. Canaan’s focus areas include Consumer Tech, Enterprise, Fintech, Frontier Tech and Life Sciences. To learn more about our people and our portfolio, please visit canaan.com.

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company’s platform of unique molecular entities selectively affects inflamed nociceptors. Treatment using this approach aims to provide more durable and robust local analgesic effects while minimizing numbness or paralysis and other systemic off-target effects. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons including chronic cough, pain and itch.